A newsletter for those involved in clinical trials. Published 20 times a year by Canary Ltd

Good Manufacturing Practice

The following articles on this topic have been published in CRAdvisor (CRA) – the year, issue number and starting page number for each are listed below:

Back to index

2007  
CRA 2007; 184:6 Regulatory inspections of a CRO.
CRA 2007; 185:2 GMP guidelines on quality risk management undergoes revision.
CRA 2007; 187:1 Annex 11 of GMP to be revised.
CRA 2007; 189:8 2007 Edition of the 'Orange Guide'.
CRA 2007; 190:4 How to avoid inspection problems with the product specification file.
CRA 2007; 192:6 Coordination of pre-approval GxP inspections.
CRA 2007; 195:7 News from the DIA conference.
   
2006  
CRA 2006; 169:1 Grey areas at GCP/GMP interface.
CRA 2006; 172:8 FDA abandons Phase I GMP plans.
CRA 2006; 177:8 FDA orders company to cease manufacturing human cells and tissues.
CRA 2006; 180:8 cGMP quality systems guidance.
CRA 2006; 181:6 Experiences of regulatory inspections at a CRO.
   
2005  
CRA 2005; 144:4 European Directives affecting clinical trials in 2005: an overview.
CRA 2005; 147:8 Authorisations for manufacturing and import.
CRA 2005; 148:6 US marshals seize products.
CRA 2005; 149:1 European Commission Directive on GCP 2005/28/EC now published.
   
2004  
CRA 2004; 123:6 New EU GMP Directive.
CRA 2004; 130:7 Guidance on transitional arrangements for QPs.
CRA 2004; 132:5 The EC-Japan MRA.
CRA 2004; 132:5 Revision of Annex 1 of EC GMP.
CRA 2004; 132:5 Statement on the Qualified Person's discretion.
CRA 2004; 134:7 FDA awards for two Swiss inspectors.
CRA 2004; 134:7 New GMP certification in China.
CRA 2004; 135:1 Long-awaited Commission Directive on GCP released for consultation.
CRA 2004; 141:7 FDA regulation of pharmaceutical manufacturing.
   
2003  
CRA 2003; 106:5 Regulation of pharma-manufacturing.
CRA 2003; 106:6 German GMP updates now on EMEA website.
CRA 2003; 115:8 New version of Annex 13 to GMP has been released.
CRA 2003; 116:5 Updated Good Manufacturing Practice guidance.
   
2002  
CRA 2002; 81:2 New draft of Annex 13 now available.
CRA 2002; 83:6 Mutual Recognition Agreement closer for GMP.
CRA 2002; 89:6 First detailed guidelines to support 2001/20/EC Directive now publicly available.
CRA 2002; 91:7 EU-Swiss MRA now in force.
CRA 2002; 96:6 FDA manufacturing initiative.
   
2001  
CRA 2001; 61:6 New ICH guidance.
CRA 2001; 75:5 EU GCP Directive and IMPs.
CRA 2001; 75:6 MRA clarification.
CRA 2001; 77:6 Annex 13 revision expected soon.
   
2000  
CRA 2000; 40:1 Do monitors break the law by collecting trial materials from the site? 
CRA 2000; 46:6 EU Pharmaceutical and Cosmetics Unit. 
   
1999  
CRA 1999; 24:3 All investigational products must comply with GMP.
CRA 1999; 24:4 Investigational product for trial purposes cannot be sold.
   
1998  
CRA 1998; 6:1 Details of destruction of trial supplies needed.
CRA 1998; 9:4 Resistance against ruling on destruction of trial supplies.
CRA 1998; 13:5 Trial products and labelling.
CRA 1998; 14:4 A practical approach to the retention of trial materials.
CRA 1998; 15:1 Annex 13 of the Guide to Good Manufacturing Practice.

Top